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One of the problems created by the French
and Dutch rejection of a European consti-
tution and the wrangling over the UK
rebate and CAP reform, is the real knock-
on damage to military R&D funding, at a
time when there seems to be a serious dry
up of EU R&D funding in the compound
semiconductor sector. 
Without either the consumer market
‘killer’ applications, or opportunity for 
seriously steady defence R&D funding, 
EU compound players may, in the longer
term, be in trouble.
Back in 2004, there was real hope that a
unified European defence R&D allocation
would provide a valuable shot in the arm. 
Not in the American league of course, as
the US defence market is estimated at
around $400bn, and forecast at $500bn
for 2010.The  EU only drums up, at best,
a quarter of this spend. In 2004 it came
to around $90bn: the UK ($38bn); France
($29bn); and Germany ($24bn). 
And, understandably, the US intends to
keep foreign companies out of its defence
markets. A recent bill, proposed in the US
House of Representatives would, if
passed, prevent any foreign companies
that benefit from government aid from bid-
ding for US contracts. 
Effectively that would cut out most of the
main military players. Organisations such
as EADS and BAE Systems are owners of
the state aided Airbus. Smaller entities,
such as Thales, have major government-
aided shareholders, and so would also be
excluded.
The legislation apparently was proposed
to keep EADS out of a Boeing tanker 
refuelling contract. EADS is now to partner
Northrop Grumman on the bid, so the pro-
posed legislation may, but may not, fall by
the wayside. 
What will not go away is Europe’s inability
to generate R&D funding for this small,
but critically useful materials sector, which
largely depended on military funding for
its emergence and early survival.
Any EU attempt to win crumbs off a US 
military contracts table is by the consor-
tium or joint venture approach, as in
Augusta-Westland, owned by
Finmeccanica SpA, partnering with
Lockheed Martin and Bell Helicopter to
win the ‘Marine One’ fleet for the US presi-
dent. In the UK, BAE Systems prefers the
acquisition route, as in its $4bn buy up of
United Defense Industries. 
But, neither consortium, nor JV, nor owner-
ship allows EU companies to acquire,
or own US technology. High tech 
companies remain US based, US nurtured,
US managed and well US funded.
As playing fields go, for the EU, this one
seems not only bumpy, but even L-shaped.
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